{"id":4468,"date":"2025-03-31T18:12:09","date_gmt":"2025-03-31T18:12:09","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/vinorelbine-txt\/"},"modified":"2025-03-31T18:12:09","modified_gmt":"2025-03-31T18:12:09","slug":"vinorelbine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/vinorelbine-txt\/","title":{"rendered":"Vinorelbine.txt"},"content":{"rendered":"<p><H3>  CLINICAL USE <\/H3>  Treatment of advanced breast cancer   (where other anthracyclines have failed) Non-small cell lung cancer   <H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3> Oral: 60\u201380 mg\/m2 once weekly for 3 weeks IV: 25\u201330 mg\/m2 once a week Maximum 60 mg per dose <H3>  PHARMACOKINETICS    <\/H3> <LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : 1079.1 (as tartrate) <\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : 13.5 (78% bound to platelets) <\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : 18.5 <\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp : &gt;40 <\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp : 28\u201344 <H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4> <LI> 20 to 50  &amp;nbsp &amp;nbsp : Dose as in normal renal function and monitor closely <LI> 10 to 20  &amp;nbsp &amp;nbsp : Dose as in normal renal function and monitor closely <LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Dose as in normal renal function and monitor closely <H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3> <LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp: Unlikely to be dialysed. Dose as in normal renal function and monitor closely <\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Unlikely to be dialysed. Dose as in normal renal function and monitor closely <LI>HDF\/high flux  &amp;nbsp : Unknown dialysability. Dose as in normal renal function and monitor closely <LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp: Unknown dialysability. Dose as in normal renal function and monitor closely <H3> IMPORTANT DRUG INTERACTIONS  <\/H3> Potentially hazardous interactions with other drugs\n<li>Antipsychotics: avoid concomitant   use with clozapine (increased risk of agranulocytosis) <H3> ADMINISTRATION  <\/H3> <H4> Reconstition<\/H4> \u2013 <H4>  Route  <\/H4> Oral, IV bolus, infusion   <H4>  Rate of Administration  <\/H4> Bolus: 5\u201310 minutes   Infusion: 20\u201330 minutes   <H4>Comments<\/H4> Dilute bolus in <LI> 20 to 50  &amp;nbsp &amp;nbsp : mL with sodium   chloride 0.9% Dilute infusion in 125 mL with sodium   chloride 0.9% Stable for 24 hours at 2\u20138\u00b0C   <H4>  OTHER INFORMATION  <\/H4> Widely distributed in the body, mostly   in spleen, liver, kidneys, lungs, thymus; moderately in heart, muscles; minimally in fat, brain, bone marrow. High levels are found in both normal and malignant lung tissues, with slow diffusion out of tumour tissue Metabolism appears to be hepatic.   Excretion is mainly by the biliary route (18.5% appears in the urine) Flush line with saline after infusion   Dose-limiting toxicity is mainly   neutropenia In patients where &gt;75% of the liver   volume has been replaced by metastases, it is empirically suggested that the dose be reduced by a third, with close haematological follow-up .<br \/>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Treatment of advanced breast cancer (where other anthracyclines<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4468","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4468"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4468\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}